← back to search

Michael K. Cooper

Servier (France) · US
Area of research
Molecular Biology · Genetics
Research interest
Research interests include Hedgehog Signaling Pathway Studies, Glioma Diagnosis and Treatment, Epigenetics and DNA Methylation, and Acute Myeloid Leukemia Research.
h-index
34
citations
11,731
works
80
NIH funding
primary concept
Medicine
email

Recent publications

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Nature Communications 2025cited by 31position: middledoi
ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip
Nature Genetics 2025cited by 11position: middledoi
Failure of human rhombic lip differentiation underlies medulloblastoma formation
Nature 2022cited by 157position: middledoi
Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation
Nature 2022cited by 4position: middledoi
The transcriptional landscape of Shh medulloblastoma
Nature Communications 2021cited by 94position: middledoi
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Blood 2020cited by 232position: middledoi
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions
Blood 2018cited by 61position: middledoi
Intertumoral Heterogeneity within Medulloblastoma Subgroups
Cancer Cell 2017cited by 1,246position: middledoi
Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial
Blood 2017cited by 25position: middledoi
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
The Lancet Oncology 2016cited by 368position: middledoi
EAG2 potassium channel with evolutionarily conserved function as a brain tumor target
Nature Neuroscience 2015cited by 96position: middledoi
Cytogenetic Prognostication Within Medulloblastoma Subgroups
Journal of Clinical Oncology 2014cited by 313position: middledoi
Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system
Journal of NeuroVirology 2014cited by 186position: middledoi
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Acta Neuropathologica 2013cited by 167position: middledoi
Subgroup-specific structural variation across 1,000 medulloblastoma genomes
Nature 2012cited by 918position: middledoi

Grants

The Physics of Satellite Galaxy Quenching: Novel Analysis of Observations, and High-Resolution Simulations
NSF1815475$347,2812018–2023PIRePORTER
Collaborative Research: The GOGREEN Survey - Caring about the Environment
NSF1518257$495,7042015–2020PIRePORTER

Frequent collaborators

Salah Nabhan · Agios Pharmaceuticals (United States)2 papers (2017–2025)Caroline Almon · Agios Pharmaceuticals (United States)2 papers (2017–2025) · 1 papers (2014–2014)Fair M. Vassoler · Tufts University1 papers (2014–2014)Hartmut Döhner · Medizinische Hochschule Hannover1 papers (2017–2017) · 1 papers (2014–2014)Peng He · Boston University1 papers (2025–2025)Mohammad Ismail Hossain · Boston University1 papers (2025–2025)Vickie Zhang · Agios Pharmaceuticals (United States)1 papers (2017–2017)Stephanie A. Cross · University of North Texas1 papers (2014–2014) · 1 papers (2017–2017) · 1 papers (2025–2025)Martin S. Tallman · Midwestern University1 papers (2017–2017)Michael G. White · University of Pennsylvania1 papers (2014–2014) · 1 papers (2014–2014)Janice E. Clements · Johns Hopkins Medicine1 papers (2014–2014) · 1 papers (2014–2014)Sophie Postel‐Vinay · Inserm1 papers (2025–2025)Amir T. Fathi · University of Southern California1 papers (2017–2017)Courtney D. DiNardo · The University of Texas MD Anderson Cancer Center1 papers (2017–2017)